BeOne Medicines Ltd.
HealthcareNASDAQ:ONC · NASDAQ Global Market
+$4.65 today
Vol 0.19M · Avg 0.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.6%
avg -25.2%
ROIC
4.7%
avg -30.0%
ROA
3.5%
avg -25.1%
Analysis
ROE is currently the strongest return metric at 6.6% versus its period average of -25.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | $4.25M | — | 63 | $40.00 | <0.01% |
John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | $2.94M | — | 58 | $1,120.00 | <0.01% |
Wang Lai | President and Global Head of Research & Development | $1.32M | — | 48 | $40.00 | <0.01% |
Aaron Rosenberg | Chief Financial Officer | $1.27M | — | 49 | $294,346.00 | 0.28% |
Chan Lee | General Counsel, Senior VP & Corporate Secretary | $1.26M | — | 58 | $160.00 | <0.01% |
Mark Lanasa | Senior Vice President & Chief Medical Officer for Solid Tumors | — | — | — | — | — |
Eleanor Duff | Senior Vice President & Head of Corporate Communications | — | — | — | — | — |
Graham Hardiman | Global Head of Human Resources | — | — | — | — | — |
Titus Ball | Vice President & Chief Accounting Officer | — | — | 52 | $36.00 | <0.01% |
Marcello Damiani | Chief Technology Officer | — | — | 56 | — | — |
Liza Heapes | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
112
$101.80M
Net Sentiment
$101.80M
Net selling
Most Active
OYLER JOHN
35 transactions
1–10 of 112
Analysis
Insiders reported 0 buys worth $0.00 and 112 sells worth $101.80M over the last 12 months. That adds up to net selling of $101.80M. OYLER JOHN was the most active insider with 35 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +163.5% | +33.8% (13yr)15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Recent growth has been strongest in Revenue at +163.5% over three years. Forward estimates point to Revenue at +33.8% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Humana Inc.
NYSE:HUM
$45.35B
Agilent Technologies, Inc.
NYSE:A
$36.58B
Alcon Inc.
NYSE:ALC
$32.54B
Natera, Inc.
NASDAQ:NTRA
$30.14B
IQVIA Holdings Inc.
NYSE:IQV
$29.94B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.56B
ResMed Inc.
NYSE:RMD
$28.06B
Koninklijke Philips N.V.
NYSE:PHG
$25.66B
Mettler-Toledo International Inc.
NYSE:MTD
$22.91B
Insmed Incorporated
NASDAQ:INSM
$21.23B
Who manages ONC?
BeOne Medicines Ltd. (ONC) lists 11 active executives. The top listed executive is Wang Lai, President and Global Head of Research & Development.
Are ONC insiders buying or selling?
Recent insider activity shows net selling of $101.86M.
Explore More
Continue the stock analysis
Jump to another research area for this company.